We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Captopril (ACE inhibitor)
An ACE-inhibitor blood-pressure/heart drug studied as a geroprotector by targeting the renin-angiotensin system. ACE inhibition extends lifespan in C. elegans (and captopril specifically modulates a worm aging pathway), and the class has decades of human cardiovascular/kidney-protective evidence — but human longevity itself is unproven. A prescription drug used off-label, not a supplement.
Prescription medication — not a dietary supplement
Captopril is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Captopril studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1979–2026 with a typical study size of 88 participants.
Based on 715 studies · 1 meta-analysis · 706 RCTs · 2,872 total participants
Confidence
High confidenceBy outcome
ACE/renin-angiotensin inhibition is a conserved aging pathway — captopril and ACE inhibitors extend lifespan in C. elegans and reduce cardiovascular/cardiac aging in rodents — and the class has strong human cardiovascular/renal outcome data, but no human trial shows captopril extends lifespan, so the geroprotector use is mechanistically grounded yet unproven.
712 rigorous studies
711 randomized trials · 1 meta-analyses · 0 systematic reviews
Our evidence rating for Captopril is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
13 trials ongoing or recruiting · 35 completed on ClinicalTrials.gov
4 of the completed trials have posted results
Registered trials show research momentum for Captopril, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Captopril is the prototype angiotensin-converting-enzyme (ACE) inhibitor — a cornerstone drug for hypertension, heart failure, post-myocardial-infarction care, and diabetic kidney protection.
Its geroscience interest centers on the renin-angiotensin system (RAS), an ancient signaling axis that, beyond blood pressure, influences inflammation, mitochondrial function, oxidative stress, and the senescence program.
Inhibiting ACE/RAS has emerged as a candidate longevity intervention with cross-species support: ACE inhibition extends lifespan in the worm C. elegans, captopril specifically inhibits the worm ACE homolog ACN-1 to influence dauer formation and aging, and reviews now frame RAS modulation as a conserved aging pathway across C. elegans, Drosophila, and rodents (where ACE inhibitors reduce cardiac and vascular aging).
On the human side, the evidence base is unusually deep — but it is cardiovascular and renal, not longevity: large randomized trials show ACE inhibitors reduce mortality and morbidity in heart failure and after myocardial infarction (e.g. the captopril arm of VALIANT) and slow kidney-disease progression.
The honest distinction is that no human trial shows captopril extends lifespan or healthspan in healthy people; the longevity case rests on conserved model-organism biology plus the drug's real (but disease-specific) human outcome benefits.
It is generally well tolerated; the characteristic effects are a dry cough (bradykinin-mediated), possible high potassium, first-dose hypotension, and a contraindication in pregnancy. Captopril is a prescription drug used off-label for its proposed geroprotective/RAS effects; it is not a dietary supplement.
The score reflects a conserved, mechanistically attractive aging pathway plus strong human cardiovascular evidence, against unproven human longevity.
Captopril blocks angiotensin-converting enzyme, lowering angiotensin II and modulating the renin-angiotensin system — a conserved axis influencing aging, inflammation, and mitochondrial function.
ACE inhibition raises bradykinin and nitric-oxide signaling (vasodilation and the characteristic cough), with vascular-protective effects.
In C. elegans, captopril inhibits the ACE homolog ACN-1 to affect dauer/aging; RAS modulation extends lifespan across invertebrate models.
How Captopril works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Contraindicated — ACE inhibitors cause fetal harm.
Monitor kidney function and potassium closely.
Caution — first-dose hypotension; start low.
Additive hyperkalemia risk — can be dangerous.
Reduce ACE-inhibitor effect and can worsen renal function (the 'triple whammy' with diuretics).
ACE inhibitors raise lithium levels and toxicity risk.
Tip: Bradykinin-mediated; switch to an ARB if intolerable.
Tip: Monitor potassium; avoid potassium supplements/salt substitutes.
Tip: Stop immediately and seek care; a class effect, more common in some groups.
Captopril has an evidence score of 3.5/10 — emerging evidence based on 518 indexed studies. An ACE-inhibitor blood-pressure/heart drug studied as a geroprotector by targeting the renin-angiotensin system. ACE inhibition extends lifespan in C. elegans (and captopril specifically modulates a worm aging pathway), and the class has decades of human cardiovascular/kidney-protective evidence — but human longevity itself is unproven. A prescription drug used off-label, not a supplement. Representative study: PMID 14610160.
The commonly studied dose of Captopril is Off-label longevity use mirrors low antihypertensive dosing (captopril is short-acting; longer-acting ACE inhibitors like lisinopril/ramipril are often used) under a clinician. Not an approved longevity regimen; blood pressure and potassium should be monitored.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Captopril — consistent daily use matters more than the time of day. Captopril is taken on an empty stomach (food reduces absorption); it is short-acting (2–3×/day).
Captopril should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are dry cough, hyperkalemia, angioedema. Use caution if any of these apply to you: Pregnancy (fetal harm); History of ACE-inhibitor angioedema; Bilateral renal artery stenosis.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Red Yeast Rice
Likely helpsFermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Beta-Sitosterol
Likely helpsPlant sterol that reduces BPH urinary symptoms in clinical trials and blocks intestinal cholesterol absorption.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 715 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research